Kim Seon Young, Lee Younghak, Kang Yea Eun, Kim Ji Min, Joung Kyong Hye, Lee Ju Hee, Kim Koon Soon, Kim Hyun Jin, Ku Bon Jeong, Shong Minho, Yi Hyon Seung
Department of Laboratory Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Endocrinol Metab (Seoul). 2018 Sep;33(3):380-386. doi: 10.3803/EnM.2018.33.3.380.
Type II autosomal dominant osteopetrosis (ADO II) is a rare genetically heterogeneous disorder characterized by osteosclerosis and increased bone mass, predominantly involving spine, pelvis, and skull. It is closely related to functional defect of osteoclasts caused by chloride voltage-gated channel 7 () gene mutations. In this study, we aimed to identify the pathogenic mutation in a Korean patient with ADO II using whole exome sequencing.
We evaluated the clinical, biochemical, and radiographic analysis of a 68-year-old woman with ADO II. We also performed whole exome sequencing to identify pathogenic mutation of a rare genetic disorder of the skeleton. Moreover, a polymorphism phenotyping program, Polymorphism Phenotyping v2 (PolyPhen-2), was used to assess the effect of the identified mutation on protein function.
Whole exome sequencing using peripheral leukocytes revealed a heterozygous c.296A>G missense mutation in the gene. The mutation was also confirmed using Sanger sequencing. The mutation c.296A>G was regarded to have a pathogenic effect by PolyPhen-2 software.
We detect a heterozygous mutation in gene of a patient with ADO II, which is the first report in Korea. Our present findings suggest that symptoms and signs of ADO II patient having a c.296A>G mutation in may appear at a very late age. The present study would also enrich the database of mutations and improve our understanding of ADO II.
II型常染色体显性遗传性骨硬化症(ADO II)是一种罕见的遗传性异质性疾病,其特征为骨硬化和骨量增加,主要累及脊柱、骨盆和颅骨。它与氯离子电压门控通道7(CLCN7)基因突变导致的破骨细胞功能缺陷密切相关。在本研究中,我们旨在通过全外显子组测序确定一名韩国ADO II患者的致病突变。
我们对一名68岁的ADO II女性患者进行了临床、生化和影像学分析。我们还进行了全外显子组测序以确定一种罕见骨骼遗传病的致病突变。此外,使用多态性表型分析程序Polymorphism Phenotyping v2(PolyPhen-2)评估所鉴定突变对蛋白质功能的影响。
使用外周血白细胞进行全外显子组测序发现CLCN7基因存在杂合性c.296A>G错义突变。该突变也通过桑格测序得到证实。PolyPhen-2软件认为c.296A>G突变具有致病作用。
我们在一名ADO II患者的CLCN7基因中检测到杂合突变,这是韩国的首例报告。我们目前的研究结果表明,CLCN7基因存在c.296A>G突变的ADO II患者的症状和体征可能在很晚的年龄才出现。本研究还将丰富CLCN7基因突变数据库,并增进我们对ADO II的理解。